Re: Nasolacrimal Stents in the Treatment of Epiphora: Long-term Results

Paúl, Laura; Pinto, Isabel; Vicente, J.; Armendariz, Ana; Moreno, Gema; Baraibar, M. Cruz

doi:10.1016/s1051-0443(07)61998-8

Cited by 5 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparing the results of all existing studies the conclusion met in the present study could almost be expected, however failed to be proven so far. The longer the follow-up period (6 months, 1 year, 2 years) [8,9,11,12,13,21,28,29] the lower was the success rate or the rate of patent stents. The early postoperative [2] to early medium-term [3] results of our patients (i.e.…”

Section: Discussionmentioning

confidence: 99%

Polyurethane stents for lacrimal duct stenoses: 5-year results

Bertelmann

Rieck

2005

Graefe's Arch Clin Exp Ophthalmo

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Polyurethane stents for lacrimal duct stenoses: 5-year results

Bertelmann

Rieck

2005

Graefe's Arch Clin Exp Ophthalmo

View full text Add to dashboard Cite

show abstract

“…Best outcomes are reported for some favorable conditions such as acquired focal, incomplete obstructions and short distal nasolacrimal duct occlusions (5,19,24,28,(29)(30)(31)(32)(33)(34)(35)(36)(37) (Table 1).…”

Section: Balloon Dacryocystoplastymentioning

confidence: 99%

The role of interventional radiology in the treatment of epiphora

Patella¹,

Panella²,

Zannoni³

et al. 2018

Gland Surg.

View full text Add to dashboard Cite

Epiphora is a relatively common ophthalmologic affection representing almost 5% of clinical consultations in ophthalmology and it consists in the complete or partial obstruction of nasolacrimal duct, leading to insufficient drainage of tears. The traditional treatment is represented by surgery namely, external dacryocystorhinostomy (DCR). Despite the high success rate DCR has many disadvantages and limitations since it requires general anesthesia, it may arise in a permanent facial scar and it is often affected by the reobstruction of the anastomotic tract by fibrotic scars and osteogenic activity. Fluoroscopically guided interventional procedures are a therapeutic alternative to surgery for lacrimal duct system obstructions that can consist either in balloon dacryocystoplasty or in nasolacrimal stent placement. In both cases, a pre-operative imaging characterization of the occlusion is needed for a correct treatment planning. In this review, we propose to highlight the role of interventional radiology in the treatment of epiphora and the role of computed tomography dacryocystography (CTD) in depiction and the pre-interventional planning.

show abstract

“…This is a relatively noninvasive procedure that is performed on an outpatient basis with sedation and local anesthesia. 50,51 Punctoplasty is a surgical procedure that enlarges the opening to the lacrimal canaliculus so that stent insertion can be performed. 52 This may be necessary in more severe cases of epiphora where simple stent placement is not successful.…”

Section: Epiphoramentioning

confidence: 99%

Docetaxel-Associated Epiphora

Kintzel¹,

Michaud

Lange

2006

Pharmacotherapy

View full text Add to dashboard Cite

Docetaxel is a semisynthetic taxane indicated for the treatment of advanced breast, prostate, and non-small cell lung cancers; it is also used for the treatment of various other solid tumors. The standard intermittent dosage of docetaxel is 60-100 mg/m2 every 3 weeks. At this dose and schedule, myelosuppression is common and neutropenia is usually the dose-limiting toxicity. Weekly administration of docetaxel 20-42 mg/m2 is being tested in the treatment of advanced solid tumors in order to improve patient tolerance by reducing the interval dose and to maintain therapeutic efficacy by increasing overall dose intensity. Asthenia and peripheral neuropathy can limit continued administration of weekly docetaxel. Epiphora (excess tearing due to narrowing or blockage of the lacrimal outflow passages) is associated with repeated weekly administration of docetaxel. This adverse effect can interfere with activities of daily life and negatively affect quality of life. Epiphora may be an underreported adverse effect of treatment because of underrecognition by clinicians and patient embarrassment with respect to seemingly uncontrolled tearing. The use of weekly docetaxel administration is expanding; therefore, patients should be educated to recognize and report signs and symptoms of epiphora. It is important for clinicians participating in the care of patients undergoing treatment with docetaxel to monitor for excess tearing and signs of eye irritation to ensure timely management of treatment-related epiphora.

show abstract

Re: Nasolacrimal Stents in the Treatment of Epiphora: Long-term Results

Cited by 5 publications

References 10 publications

Polyurethane stents for lacrimal duct stenoses: 5-year results

Polyurethane stents for lacrimal duct stenoses: 5-year results

The role of interventional radiology in the treatment of epiphora

Docetaxel-Associated Epiphora

Contact Info

Product

Resources

About